Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The phrase "Purine metabolism/DNA synthesis inhibition via incorporation into DNA by lymphocytes" combines two overlapping but distinct biochemical processes and is not a standard canonical target. Purine metabolism encompasses a network of enzymes and steps essential for the production and recycling of purine nucleotides required for DNA and RNA synthesis. Enzymatic targets within the purine biosynthesis pathway (such as amidophosphoribosyltransferase, GAR synthetase, PAICS, ATIC, and others) are essential in rapidly dividing cells, including lymphocytes, where DNA synthesis is high[1][5]. DNA synthesis inhibition in lymphocytes is therapeutically targeted via drugs and mechanisms that disrupt purine metabolism, such as methotrexate (which inhibits dihydrofolate reductase and depletes precursors for purine biosynthesis), cytarabine (an antimetabolite incorporated into DNA), and actinomycin D. These interventions either deplete pools of purine nucleotides or are incorporated into DNA, thereby terminating chain elongation or causing DNA damage[2][5][3]. Inhibiting purine metabolism can impair DNA repair and cell proliferation, making this pathway a key target in oncology (especially for leukemias and lymphomas) and immunosuppression[3][1]. The precise target here is not a single molecule or enzyme, but rather several enzymes within the purine biosynthesis pathway (collectively or via the multienzyme "purinosome" complex)[1]. Therefore, the original target name is too broad and lacks the specificity typically expected in a therapeutic target definition. It is best described as a pathway-level target encompassing specific enzymes involved in de novo purine synthesis, which can be disrupted to inhibit lymphocyte proliferation or DNA synthesis in pathological contexts such as cancer or autoimmune disease[1][5][3].
Inhibition of de novo purine synthesis; Inhibition of DNA synthesis via nucleotide depletion or incorporation of antimetabolites into DNA[5][2][3]
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Purine metabolism enzymes involved in DNA synthesis (null).